Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer, autoimmune diseases, inflammatory conditions, and neurodegenerative disorders. The company leverages its proprietary G-MAB antibody library to create a diverse range of treatments, including chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates. Key products in development include anti-CD38 CAR-T therapy for multiple myeloma and a non-opioid neurotoxin, resiniferatoxin, aimed at treating severe pain in late-stage cancer and osteoarthritis. Sorrento also explores drug delivery technologies such as Sofusa, which targets the lymphatic system, and ZTlido, a lidocaine delivery system for postherpetic neuralgia. Additionally, the company is involved in various collaborations to enhance its research and development efforts, including projects focused on COVID-19 therapeutics. With a commitment to addressing significant unmet medical needs, Sorrento Therapeutics aims to advance its diverse pipeline through both innovative drug development and strategic partnerships.
Top Stages
https://app.dealroom.co/companies/***
https://crunchbase.com/organization/***
https://linkedin.com/company/***
11 past transactions
Ancora Medical
Acquisition in 2022
Ancora Medical is a privately held medical technology company specializing in innovative catheter technology aimed at enhancing surgical pain management. Its core product combines an anchoring catheter with a needle, designed to administer long-lasting anesthesia during the preoperative, perioperative, and postoperative phases of both general and orthopedic surgeries. The company's technology effectively locates peripheral nerves by utilizing electrical impulses from a nerve stimulator in conjunction with ultrasound visualization, providing healthcare professionals with an affordable and reliable system for managing surgical pain.
Virex Health
Acquisition in 2022
Virex Health is a biotechnology company that specializes in the development of rapid point-of-care diagnostic kits. These innovative kits utilize a glucometer and a novel glucometer-based test strip to deliver affordable and highly scalable diagnostic services. Virex Health focuses on a range of applications, including COVID-19 testing and early cancer detection, allowing for widespread testing across various environments such as homes, workplaces, schools, and public spaces globally. The company's commitment to advanced diagnostics aims to enhance accessibility and efficiency in health monitoring and disease detection.
Aardvark Therapeutics
Series B in 2021
Founded in 2017, Aardvark Therapeutics is a biopharmaceutical company dedicated to developing small molecule therapeutics targeting metabolic diseases. Its lead product candidate, ARD-101, is an oral gut-restricted therapy designed to selectively activate bitter taste receptors for hunger-associated conditions.
Celularity
Post in 2021
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies targeting various diseases, including cancer, infectious, and degenerative conditions.
ACEA Therapeutics
Acquisition in 2021
ACEA Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative drugs for the treatment of lung cancer, lymphoma, and systemic lupus erythematosus. Incorporated in 2017 and headquartered in San Diego, California, with additional operations in Hangzhou and Quzhou, China, ACEA is dedicated to enhancing patient outcomes through its diverse portfolio of therapeutic candidates, including Abivertinib, AC0058, AC0002, and AC0078. The company specializes in both targeted therapies and immunotherapeutic approaches, underpinned by a robust research and development framework. ACEA has also established drug manufacturing and commercial capabilities in China, allowing for better control over the supply chain and ensuring timely delivery of high-quality products. By focusing on chronic and life-threatening diseases, ACEA Therapeutics aims to provide effective treatments that significantly improve patients' lives.
SmartPharm Therapeutics
Acquisition in 2020
SmartPharm Therapeutics, Inc. is a privately held biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company specializes in the development of non-viral gene therapies aimed at treating serious or rare diseases. With a focus on creating biologics from within, SmartPharm is advancing a pipeline of gene-encoded therapeutics that enable patients' cells to produce necessary proteins for conditions requiring biologic treatment, such as enzyme replacement and tissue restoration. Their innovative platform emphasizes minimally immunogenic and re-dosable therapies, alongside scalable and economically feasible manufacturing processes. By leveraging insights from prior gene therapy developments and integrating advanced technologies, SmartPharm Therapeutics aims to deliver effective treatments while minimizing the regulatory complexities associated with traditional gene therapies. As of September 2020, the company operates as a subsidiary of Sorrento Therapeutics, Inc.
Celularity
Venture Round in 2018
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies targeting various diseases, including cancer, infectious, and degenerative conditions.
Semnur Pharmaceuticals
Acquisition in 2016
Semnur Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company dedicated to the development of innovative non-opioid drugs aimed at treating lumbar radicular pain. The company focuses on creating products that address the needs of pain management practitioners and their patients, particularly those who are underserved in terms of effective back pain treatment. By emphasizing clinical and commercial development, Semnur aims to enhance the efficacy and safety of pain management solutions, thereby improving outcomes for individuals suffering from back pain.
Scilex Pharmaceuticals
Acquisition in 2016
Scilex Pharmaceuticals is an emerging company focused on acquiring and commercializing late-stage prescription products with improved delivery solutions for treating pain. Its primary product, ZTlido, is a topical lidocaine system for relieving postherpetic neuralgia pain.
Globavir Biosciences
Venture Round in 2015
Founded in 2011 by Dr. Shalabh Gupta, Globavir Biosciences focuses on developing therapeutics and diagnostics for global infectious diseases. The company operates through its subsidiary BioCycive, which has partnered with Sorrento Therapeutics and Bio-Rad to advance its lead programs.
NantiBodyFc
Private Equity Round in 2015
NantiBodyFc operates in the healthcare industry. Founded in 2015, the company is headquartered in Cumming, Georgia, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.